Admin_Adham
Jump to Key Points The FDA has approved Ryzumvi eye drops to treat presbyopia in adults, according to a press release from Viatris, which markets the product.
Ryzumvi is a prescription eye drop containing 0.75% phentolamine ophthalmic solution. It is intended to improve near vision in adults with presbyopia, an age-related condition that makes focusing on close objects difficult.
The medication was approved in 2023 to treat pharmacologically induced mydriasis, or pupil dilation, in adults and children ages 3 years or older.
Ryzumvi is not recommended for patients with active eye inflammation, such as iritis. To reduce the risk for eye injury or contamination, patients should avoid touching the vial tip to the eye or any other surface, according to the release.
- FDA approved Ryzumvi 0.75% phentolamine ophthalmic solution for adult presbyopia.
- Indication: improve near vision in adults with age-related presbyopia.
- Previously approved in 2023 for pharmacologically induced mydriasis, ages ≥3 years.
- Avoid use with active eye inflammation, incl iritis.
- Common AEs: conjunctival hyperemia; instillation-site irritation/pain/stinging/burning.
Patients who wear contact lenses should remove them before using Ryzumvi and wait at least 10 minutes after dosing before reinserting them, according to the release.
The most common side effects of Ryzumvi when used to treat presbyopia include conjunctival hyperemia, or eye redness, and irritation at the site of instillation, the release said.
When used to treat pharmacologically induced mydriasis, the most common side effects include discomfort at the site of instillation, including pain, stinging and burning, as well as conjunctival hyperemia, according to Viatris.
Viatris holds exclusive US commercialization rights to the drug through a licensing agreement with Opus Genetics.
